IFN-α has also been successfully used for the treatment of patients with chronic myeloid leukemia (CML) [13] and Non-Hodgkin lymphoma (NHL) [14]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.